Kazumasa Akita-Ito
Minato, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.
Journal: Eye (London, England)
Published: October 21, 2023
Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study.
Journal: Eye (London, England)
Published: May 12, 2023
Nucleic acid ligands act as a PAM and agonist depending on the intrinsic ligand binding state of P2RY2.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 29, 2021
Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.
Journal: Molecular therapy. Nucleic acids
Published: April 27, 2019
Alkaline-tolerant RNA aptamers useful to purify acid-sensitive antibodies in neutral conditions.
Journal: Biochimie
Published: September 09, 2017
How protein reads the stop codon and terminates translation.
Journal: Genes to cells : devoted to molecular & cellular mechanisms
Published: July 31, 1998
Showing 1-8 of 8
Last Updated: 09/26/2026